Results 111 to 118 of about 28,236 (118)

Dipeptidyl Peptidase-4 Inhibitors, Peripheral Arterial Disease, and Lower Extremity Amputation Risk in Diabetic Patients

American Journal of Medicine, 2017
Chun-Chin Chang, Hsin-Bang Leu, Yung-Tai Chen   +2 more
exaly  

Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes

Expert Opinion on Therapeutic Patents, 2003
Koen Augustyns, Pieter Van der Veken, Achiel Haemers   +2 more
exaly  

The risk of fragility fractures in new users of dipeptidyl peptidase-4 inhibitors compared to sulfonylureas and other anti-diabetic drugs: A cohort study

Diabetes Research and Clinical Practice, 2018
John-Michael Gamble, , William Midodzi
exaly  

Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Disproportionality Analysis Based on the Japanese Adverse Drug Event Report Database

Diabetes Care, 2018
Jun Shirakawa, Yasuo Terauchi, Shirakawa Jun   +2 more
exaly  

Dipeptidyl nitriles as human dipeptidyl peptidase I inhibitors

Bioorganic and Medicinal Chemistry Letters, 2006
John Pedersen
exaly  

Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs

Expert Opinion on Investigational Drugs, 2005
Rolf Mentlein
exaly  

Dipeptidyl peptidase IV inhibitors derived from β-aminoacylpiperidines bearing a fused thiazole, oxazole, isoxazole, or pyrazole

Bioorganic and Medicinal Chemistry Letters, 2005
Ann Weber, Huaibing He, Kathryn A Lyons   +2 more
exaly  

Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: Close analogs of JANUVIA™ (sitagliptin phosphate)

Bioorganic and Medicinal Chemistry Letters, 2007
Ann Weber, Huaibing He, Kathryn A Lyons   +2 more
exaly